Evaluation of IGFBP5 expression and plasma osteopontin level in COVID-19 patients

Basit Öğe Kaydı
dc.contributor.authorKarabulut-Uzuncakmak, Sevgi
dc.contributor.authorAksakal, Alperen
dc.contributor.authorKerget, Ferhan
dc.contributor.authorAydin, Pelin
dc.contributor.authorHalıcı, Zekai
dc.date.accessioned2026-02-28T12:08:58Z
dc.date.available2026-02-28T12:08:58Z
dc.date.issued2023
dc.departmentBayburt Üniversitesi
dc.description.abstractPurpose: The aim of this study is to investigate insulin-like growth factor binding protein 5 (IGFBP5) expression in coronavirus disease 2019 (COVID-19) patients and its relationships with COVID-19 laboratory findings and plasma osteopontin (OPN) levels. Materials and methods: We enrolled 60 patients with COVID-19 and 30 healthy individuals in this study. mRNA expression of IGFBP5 was measured by RT-PCR. Plasma OPN levels were measured via the ELISA method. Results: Plasma OPN levels were higher and IGFBP5 expression levels were lower in COVID-19 patients than in the healthy individuals (p ?= ?0.0057 and p ?= ?0.0142, respectively). Critically ill patients had higher OPN and lower IGFBP5 than non-critically ill patients. Patients with affected lungs demonstrated increased OPN and decreased IGFBP5 (p ?= ?0.00032 and p ?= ?0.044, respectively). Receiver operating characteristic (ROC) analysis indicated that IGFBP5 expression and OPN levels can be used discriminate non-critically from critically ill patients (p ?= ?0.049; p ?= ?0.0016, respectively). Conclusion: This study demonstrated that patients with a poor prognosis had increased OPN and decreased IGFBP5. High values of OPN and low values of IGFBP5 may be considered as signs of disease severity. Tissue-specific IGFBP5 expression may contribute to understanding the role of IGFBP5 in the lungs in COVID-19 cases. © 2022 Medical University of Bialystok
dc.description.sponsorship(2021/69001-01-03)
dc.identifier.doi10.1016/j.advms.2022.11.001
dc.identifier.endpage37
dc.identifier.issn18961126
dc.identifier.issue1
dc.identifier.pmid36427358
dc.identifier.scopus2-s2.0-85142455260
dc.identifier.scopusqualityQ1
dc.identifier.startpage31
dc.identifier.urihttps://doi.org/10.1016/j.advms.2022.11.001
dc.identifier.urihttps://hdl.handle.net/20.500.12403/5750
dc.identifier.volume68
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMedical University of Bialystok
dc.relation.ispartofAdvances in Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20260218
dc.subjectCOVID-19
dc.subjectCritically ill patients
dc.subjectIGFBP5
dc.subjectOPN
dc.subjectOsteopontin
dc.titleEvaluation of IGFBP5 expression and plasma osteopontin level in COVID-19 patients
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu